本帖最后由 风雨不动 于 2012-4-14 14:43 编辑
http://www.marketwatch.com/story/amarillo-biosciences-issues-corporate-update-2011-10-14
press release
Oct. 14, 2011, 5:59 p.m. EDT Amarillo Biosciences Issues Corporate Update
New Oral Interferon Studies Planned in Hepatitis B and Cancer Two new oral interferon studies are expected to start in 2012. The first will be a Phase 2 study for treatment and prevention of relapse in patients with chronic hepatitis B infection. The second will be a pilot trial to evaluate oral interferon as adjunctive therapy for certain types of cancer.
马里洛生物科学问题的企业更新
B型肝炎和癌症计划在新的口服干扰素研究
两种新的口服干扰素的研究,预计于2012年开始。首先,将第2阶段在慢性乙型肝炎患者的治疗和预防复发的研究。第二,将试点试验,以评估口服干扰素作为辅助治疗某些类型的癌症
(6.合.彩).足球.篮球...各类投注开户下注
第一投注.现金网:招代理年薪10万以上:6668.cc |